$JBIO

KXCO's FDA Ontology Ranks Lorundrostat First After Its 10 November Update

KXCO's FDA ontology at kxco.ai/fda was updated in full on 10 November 2026. Its first screen now ranks Mineralys's lorundrostat (MLYS) first of the FDA decisions due within 90 days: decision 22 December, potential return +86%, per the page. Mineralys's shares fell 24.5% between reads on 20 October and 10 November. The update read six quarterly reports to 30 September by hand, and on KXCO's calculation Mineralys is funded to 12 October 2029, even if it repays its $100.0m loan by 30 June 2028.